Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
To alleviate metastatic castration-resistant prostate cancer (mCRPC), enzalutamide, a non-steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti-androgen treatment, compensatory mechanisms in prostate cancer have been identified, leading to increased expression and funct...
Main Authors: | Ritesh P. Bhole, Payal M. Karche, Shaliendra S. Gurav, Rupesh V. Chikhale |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Results in Chemistry |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221171562300382X |
Similar Items
-
Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
by: Florian Rosar, et al.
Published: (2022-03-01) -
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
by: Vincenza Conteduca, et al.
Published: (2022-04-01) -
THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01) -
MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC
by: Yuanyuan Wang, et al.
Published: (2024-04-01) -
DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER
by: S. V. MISHUGIN, et al.
Published: (2016-12-01)